B., Skreb, F., Cepelak, I., Romic, Z., & Mayer, L
Among the most promising non-incretin receptor targets are amylin (Amy) receptors (AMYRs), supported by data from phase I and phase II clinical trials showing efficacy of the long-acting amylin and calcitonin receptor agonist, cagrilinitide (Cagri), both as monotherapy 2,3 and in combination with the selective GLP-1R agonist, semaglutide 4,5
Collagen helps maintain the thickness and elasticity of the dermis, the skin's middle layer
Metalyse has been evaluated in multiple global clinical trials and real-world studies
Cagrilintide has established itself as one of the most exciting appetite regulation peptides currently available